Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells

Molecular Medicine Reports

Volumn 3, Issue 6, 2010, Pages 1031-1034

  Ikeda, Ryuji ^a   Vermeulen, Lee C ^b   Lau, Elim ^c   Jiang, Zhisheng ^c   Pomplun, Marcia ^c   Kolesar, Jill M ^c  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Bcl XL; Curcumin; Irinotecan; Non small cell lung cancer; X linked inhibitor of apoptosis protein

Indexed keywords

CARBOPLATIN; COMPLEMENTARY DNA; CURCUMIN; DNA TOPOISOMERASE INHIBITOR; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; PACLITAXEL; PROTEIN BCL XL; RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL STRAIN A549; CELL VIABILITY; CONCENTRATION RESPONSE; LONG TERM EXPOSURE; LUNG CANCER; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 78649462719     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2010.366     Document Type: Article

References (21)

1. Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, Leighl NB, Shepherd FA, Powers J, Seymour L and Laurie SA: Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small cell lung cancer. J Clin Oncol 27: 404-410, 2009.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
3. Azzoli CG, Baker S Jr, Temin S, et al: American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small cell lung cancer. J Clin Oncol 27: 6251-6266, 2009.
4. Stewart DJ, Tomiak E, Shamji FM, Maziak DE and MacLeod P: Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer. Lung Cancer 44: 241-249, 2004.
5. Xu Y and Villalona-Calero MA: Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13: 1841-1851, 2002.
6. Rothenberg ML: Irinotecan (CPT-11): recent developments and future directions - colorectal cancer and beyond. Oncologist 6: 66-80, 2001.
7. Huang TT, Wuerzberger-Davis SM, Seufzer BJ, Shumway SD, Kurama T, Boothman DA and Miyamoto S: NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. J Biol Chem 275: 9501-9509, 2000.
8. Wang CY, Cusack JC Jr, Liu R and Baldwin AS Jr: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-417, 1999.
9. Singh S and Aggarwal BB: Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem 270: 24995-5000, 1995.
10. Anto RJ, Maliekal TT and Karunagaran D: L-929 cells harboring ectopically expressed Re1A resist curcumin-induced apoptosis. J Biol Chem 275: 15601-15604, 2000.
11. Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D and Anto RJ: Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 280: 6301-6308, 2005.
12. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107: 241-246, 2001.
13. Nakanishi C and Toi M: Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309, 2005.
14. Baldwin AS Jr: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14 649-683, 1996.
15. Webster GA and Perkins ND: Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol 19: 3485-3495, 1999.
16. Tergaonkar V, Pando M, Vafa O, Wahl G and Verma I: p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 1: 493-503, 2002.
17. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J and Aggarwal BB: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67: 3853-3861, 2007.
18. Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Mejia PE, Sood AK, McConkey DJ and Logsdon CD: Nuclear factor-kappaB p65/re1A silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res 14: 8143-8151, 2008.
19. Hernández-Vargas H, Rodríguez-Pinilla SM, Julián-Tendero M, Sánchez-Rovira P, Cuevas C, Antón A, Ríos MJ, Palacios J and Moreno-Bueno G: Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance: Breast Cancer Res Treat 102: 157-172, 2007.
20. Konstantinopoulos PA, Fountzilas E, Pillay K, Zerbini LF, Libermann TA, Cannistra SA and Spentzos D: Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC Med Genomics 1: 59, 2008.
21. Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao MS, Evans DB, Abbruzzese JL, McDonnell TJ and Chiao PJ: The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 21: 6510-6519, 2002.